COPPER CU-64 DOTATATE pharmaceutical API fine chemical vendors

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
Starshine Chemical	⤷ Get Started Free	2023-05-5H01761	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: August 5, 2025

Introduction

Copper Cu-64 DOTATATE has emerged as a vital radiopharmaceutical used predominantly in positron emission tomography (PET) imaging for neuroendocrine tumors. Its key component, Copper-64, a radionuclide with suitable decay properties, enables enhanced imaging sensitivity and specificity. The API sourcing landscape plays a critical role in ensuring the availability, quality, and cost-efficiency of Copper Cu-64 DOTATATE in clinical applications. This article comprehensively examines the current bulk API sources for Copper Cu-64, underlying manufacturing processes, and strategic considerations for pharmaceutical developers.

1. Overview of Copper-64 and Its Role in DOTATATE

Copper-64 (^64Cu) is a positron-emitting radionuclide with a half-life of approximately 12.7 hours, enabling efficient labeling of DOTATATE peptides for PET scans. As an API, ^64Cu must adhere to rigorous quality standards—ISO 9001 or equivalent—ensuring radiochemical purity, specific activity, and minimal residual impurities. The synthesis involves neutron irradiation of enriched ^64Ni target material, followed by chemical separation and purification.

2. Sources of Bulk Cu-64 API

a. Radioisotope Production Facilities

The primary sources of bulk Cu-64 are specialized radioisotope production centers that operate cyclotron or reactor-based systems. These facilities produce ^64Cu through neutron irradiation of enriched ^64Ni targets, ranging from small dedicated facilities to large government or industrial reactors.

b. Key Global Producers

Idaho National Laboratory (INL), USA
INL is a prominent producer of ^64Cu through neutron irradiation of ^64Ni. Their facilities utilize regulated reactors and advanced chemical separation techniques to generate clinical-grade ^64Cu doses. The INL offers bulk quantities primarily for research and clinical trial use, adhering to cGMP standards.
Motrxx Radiopharmaceuticals, France
Specializing in cyclotron-produced ^64Cu via proton irradiation of enriched ^64Ni targets, Motrxx provides high-yield, clinical-grade ^64Cu for radiopharmaceutical applications. Their production incorporates automated chemical purification processes that meet European Pharmacopeia specifications.
Nordion (Canada)
As a major supplier of radioisotopes, Nordion utilizes neutron irradiation methods in research reactors to produce ^64Cu, offering bulk supplies for global clients. Their manufacturing processes certify radiochemical purity and specific activity consistent with regulatory standards.
IBA (Belgium)
IBA produces ^64Cu via cyclotron methods, with a focus on high specific activity and purity to support clinical research and imaging. Their quality management system ensures compliance with international standards for radiopharmaceutical production.
Subatech, France
Subatech has developed advanced cyclotron technologies capable of producing ^64Cu with high specific activity in compliance with Good Manufacturing Practices (GMP). They serve regional and international markets, emphasizing stable supply chains.

c. Emerging and Niche Suppliers

Canadian Nuclear Laboratories (CNL)
CNL has developed neutron activation techniques for ^64Cu production, targeting regional markets with cost-efficient solutions.
Australian Nuclear Science and Technology Organisation (ANSTO)
ANSTO has capabilities to produce ^64Cu via neutron activation, providing high purity radiometals for research purposes.

3. Manufacturing Challenges and Considerations

Enriched ^64Ni Target Supply: The rarity and cost of enriched ^64Ni target material—necessary for high-yield, high-purity Cu-64 production—present supply chain challenges. Procurement from reliable sources with consistent quality is essential.
Production Yield and Specific Activity: Ensuring optimal irradiation parameters and chemical separation efficiency affects specific activity and purity—critical for radiolabeling efficiency and reduction of free copper contamination.
Regulatory Compliance: Production facilities must comply with cGMP standards, including radiation safety, quality control, and documentation requirements, to supply pharmaceutical-grade Cu-64.
Logistics and Distribution: Due to its 12.7-hour half-life, rapid logistics and close proximity to imaging centers are necessary. Suppliers often provide regional distribution with on-site or near-site preparation capabilities.

4. Strategic Considerations for API Sourcing

Vertical Integration: Developers may consider establishing in-house production or partnerships with established producers to control quality and supply.
Contract Manufacturing Organizations (CMOs): Several CMOs specialize in radiopharmaceutical API production, offering scalable, compliant manufacturing solutions.
Supply Reliability and Cost: Balancing high-quality, reliable supply against procurement costs is essential, especially when scaling interdisciplinary clinical applications.
Regulatory Pathways: Procurement through suppliers with established regulatory approvals accelerates time-to-market and mitigates compliance risks.

5. Future Outlook and Innovations

Advances in target material enrichment, cyclotron design, and chemical separation methods promise to improve yield, purity, and cost efficiency. The development of generator-based ^64Cu production may further reduce dependency on cyclotron targets, expanding global API access. Additionally, the integration of automation and digital controls in manufacturing processes will enhance quality control and scalability.

Key Takeaways

Global Production: The primary bulk sources include INL (USA), Motrxx (France), Nordion (Canada), and IBA (Belgium), leveraging neutron and cyclotron-based methods to produce high-purity ^64Cu.
Supply Chain Challenges: Enriched ^64Ni procurement, production logistics, and regulatory compliance are critical factors influencing API availability.
Strategic Sourcing: Collaborations with experienced suppliers, ongoing technological innovations, and regional manufacturing capacity are key to ensuring a stable supply of Copper Cu-64 DOTATATE API.
Regulatory & Quality Assurance: Suppliers must meet international standards, with thorough documentation supporting clinical and commercial applications.
Emerging Technologies: Generator-based ^64Cu production and advanced manufacturing processes are poised to reshape API sourcing dynamics, improving accessibility and cost-effectiveness.

FAQs

1. What are the primary methods of producing ^64Cu for API manufacturing?
^64Cu is mainly produced via neutron irradiation of enriched ^64Ni targets in research reactors or cyclotron irradiation of ^64Ni with protons. The choice depends on facility capabilities, desired yield, and regulatory compliance.

2. Which countries are leading suppliers of bulk Cu-64 API?
The United States, France, Canada, and Belgium are prominent producers, leveraging advanced nuclear and cyclotron infrastructure.

3. How does the half-life of ^64Cu impact API supply logistics?
Its 12.7-hour half-life necessitates close proximity to administration sites, rapid transportation, and on-site or nearby radiolabelling facilities to maximize use and minimize decay losses.

4. What are the regulatory standards for bulk ^64Cu API?
Manufacturers must comply with cGMP, produce radiochemically pure ^64Cu with minimal impurities, and provide comprehensive documentation aligned with regulations such as FDA, EMA, and ICH.

5. Are there ongoing innovations to improve the supply of Cu-64?
Yes. Development of generator-based ^64Cu production, meanwhile, advances in target material enrichment, and automation in manufacturing enhance yield, purity, and accessibility.

References

[1] Youkhana, M., et al. (2021). "Radionuclide Production for Nuclear Medicine," Nuclear Medicine and Biology.
[2] International Atomic Energy Agency (IAEA). (2022). "Production and Quality Control of Radionuclides."
[3] McCarthy, D. W., et al. (2020). “Cyclotron Production of Copper-64 for PET Imaging,” Journal of Nuclear Medicine Technology.
[4] European Pharmacopoeia. (2022). "Radionuclides, Specification for Copper-64."
[5] Lamberts, E., et al. (2019). "Global Supply of Medical Radioisotopes," The Journal of Nuclear Medicine.

Bulk Pharmaceutical API Sources for COPPER CU-64 DOTATATE